Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Centre Hospitalier of Chartres
- Target Recruit Count
- 37
- Registration Number
- NCT00240682
- Locations
- 🇫🇷
Hospital Charles Nicolle, Rouen, France
🇫🇷Beaujon's Hospital, Clichy, France
🇫🇷CHR of Colmar, Colmar, France
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 23
- Registration Number
- NCT00226941
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 39
- Registration Number
- NCT00226239
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2007-04-06
- Lead Sponsor
- Grupo de Investigacao do Cancro Digestivo
- Target Recruit Count
- 45
- Registration Number
- NCT00215722
- Locations
- 🇵🇹
Hospital Garcia de Orta, Almada, Portugal
🇵🇹Centro Hospitalar do Funchal, Funchal, Portugal
🇵🇹Hospital do Divino Espírito Santo, Ponta Delgada, Portugal
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Nasser Hanna, M.D.
- Target Recruit Count
- 36
- Registration Number
- NCT00216203
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00207116
- Locations
- 🇺🇸
Local Institution, Newark, Delaware, United States
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT00207155
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 55
- Registration Number
- NCT00203931
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-11-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 69
- Registration Number
- NCT00193453
- Locations
- 🇺🇸
Gainsville Hematology Oncology Associates, Gainesville, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00193219
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸Jackson Oncology Associates, Jackson, Mississippi, United States
🇺🇸Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.